Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in Obstructive Sleep Apnea
23 mai 2024 09h50 HE
|
Apnimed, Inc.
Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in Obstructive Sleep Apnea
Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea
09 mai 2024 08h00 HE
|
Apnimed, Inc.
Apnimed Completes Enrollment in Ph3 LunAIRo Study of AD109, Potential 1st Nighttime Oral Tx for Obstructive Sleep Apnea; Presents Study Design at ATS2024
Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal
07 mai 2024 08h00 HE
|
Apnimed, Inc.
Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal
Apnimed to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03 avr. 2024 08h00 HE
|
Apnimed, Inc.
Apnimed to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Apnimed to Participate in the Upcoming Leerink Partners Global Biopharma Conference
06 mars 2024 08h00 HE
|
Apnimed, Inc.
Apnimed to Participate in the Upcoming Leerink Partners Global Biopharma Conference
Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference
22 févr. 2024 08h00 HE
|
Apnimed, Inc.
Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference
Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
22 janv. 2024 07h00 HE
|
Apnimed, Inc.
Apnimed Announces New Leadership Appointments as It Builds Commercial & HR Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for OSA
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
21 déc. 2023 08h30 HE
|
Apnimed, Inc.
-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- Part of a two-study...
Apnimed to Participate in Upcoming November Investor Conferences
06 nov. 2023 08h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for Obstructive Sleep Apnea and other Sleep Disorders
31 oct. 2023 20h00 HE
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...